Windlas Biotech Limited (BOM:543329)

India flag India · Delayed Price · Currency is INR
915.65
-2.80 (-0.30%)
At close: Jun 6, 2025
43.92%
Market Cap 19.12B
Revenue (ttm) 7.60B
Net Income (ttm) 609.94M
Shares Out n/a
EPS (ttm) 28.87
PE Ratio 31.34
Forward PE n/a
Dividend 5.50 (0.60%)
Ex-Dividend Date Sep 17, 2024
Volume 1,864
Average Volume 4,589
Open 912.00
Previous Close 918.45
Day's Range 911.55 - 922.15
52-Week Range 637.30 - 1,197.00
Beta n/a
RSI 41.39
Earnings Date May 16, 2025

About Windlas Biotech

Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO solutions, including product development, licensing, and commercial manufacturing of complex drugs and dosage forms. It also produces nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprising fixed dosage combinations, fixed dosage plus modifie... [Read more]

Industry Pharmaceutical Preparations
Founded 2001
Employees 1,154
Stock Exchange Bombay Stock Exchange
Ticker Symbol 543329
Full Company Profile

Financial Performance

In 2024, Windlas Biotech's revenue was 7.60 billion, an increase of 20.43% compared to the previous year's 6.31 billion. Earnings were 609.94 million, an increase of 4.82%.

Financial Statements

News

There is no news available yet.